Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00541476
First received: October 8, 2007
Last updated: November 20, 2008
Last verified: November 2008
  Purpose

The purpose of this study is to obtain more data about efficacy and safety of the study drug Lyrica.


Condition Phase
Neuralgia
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Undergoing Symptomatic Treatment With Lyrica

Further study details as provided by Pfizer:

Enrollment: 746
Study Start Date: June 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of peripheral or central neuropathic pain

Exclusion Criteria:

  • None. Patients recruited by physician decision. Patient's personal data are not collected.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00541476

Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trials Disclosure Group, Pfizer, Inc
ClinicalTrials.gov Identifier: NCT00541476     History of Changes
Other Study ID Numbers: A0081178
Study First Received: October 8, 2007
Last Updated: November 20, 2008
Health Authority: Czech Republic: Ethics Committee

Additional relevant MeSH terms:
Neuralgia
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on April 17, 2014